18F-(2S,4R)4-fluoroglutamine

**18F-(2S,4R)4-fluoroglutamine** is an investigational radiopharmaceutical used as a positron emission tomography (PET) imaging agent. It is a fluorinated analog of natural L-glutamine in which a hydrogen atom is replaced by the positron-emitting isotope fluorine-18. The compound acts as a metabolic tracer for glutaminolysis and glutamine transport in vivo. Tumors with high glutaminolytic activity or upregulated c-MYC expression show increased uptake of this tracer, making it useful for noninvasive imaging of tumor metabolism and potentially aiding in cancer diagnosis and characterization. Its uptake occurs via native L-glutamine transporters and reflects cellular glutamine flux[1][2][3][6][8]. Preclinical studies have demonstrated its utility across various tumor models including breast cancer, lymphoma, multiple myeloma, glioblastoma-derived tumors, and other solid tumors[5][6][7]. Early clinical trials indicate that it may detect more lesions than standard FDG-PET in certain cancers such as breast cancer[6].

Other names

Fluorine-18 fluoroglutamineFluorine18 fluoroglutamineFluorine 18 fluoroglutamine[18F](2S,4R)-4-Fluoroglutamine